P. C. Kohler

发表

Phase I study of toremifene in patients with advanced cancer.

D. Haller, J. Hamm, D. Tormey, 1991 .

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

J. Hainsworth, H. Burris, D. Spigel, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

D. Alberts, G. Weiss, S. Wilczynski, 2001, Gynecologic oncology.

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

R. Bechhofer, J. Sosman, B. Storer, 1991, Cancer investigation.

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

R. Bechhofer, J. Sosman, B. Storer, 1988, Cancer research.

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

R. Bechhofer, B. Storer, J. Bradshaw, 1988, Cancer research.

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

R. Bechhofer, J. Sosman, B. Storer, 1988, Journal of the National Cancer Institute.

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

B. Chen, J. Hank, P. Sondel, 1986, Journal of immunology.

Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions

J. Hank, P. Sondel, P. C. Kohler, 2004, Cancer Immunology, Immunotherapy.

Tumor-infiltrating lymphocytes and interleukin-2 in melanomas.

J. Sosman, B. Storer, J. Hank, 1989, The New England journal of medicine.

The cellular immunotherapy of cancer: current and potential uses of interleukin-2.

J. Sosman, P. Fisch, J. Hank, 1989, Critical reviews in oncology/hematology.

Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer 1

R. Bechhofer, J. Sosman, B. Storer, 2006 .

the influence of autologous lymphokine‐activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin‐2

R. Bechhofer, J. Sosman, B. Storer, 1990, Cancer.

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.

R. Bechhofer, B. Storer, K. Moore, 1989, Cancer investigation.

Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial

J. Hank, P. Sondel, P. C. Kohler, 1985, Cancer.

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.

R. Bechhofer, J. Sosman, B. Storer, 1988, Journal of the National Cancer Institute.

Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.

G. Chung, M. DiGiovanna, Jaehyuk Choi, 2008, Clinical breast cancer.

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

R. Bechhofer, B. Storer, N. Rosenthal, 1988, Journal of biological response modifiers.

The in vivo distribution of indium-111 labeled in vitro alloactivated syngeneic lymphocytes in a patient with relapsed acute myelomonocytic leukemia: implications for adoptive chemoimmunotherapy.

J. Hank, P. Sondel, R. Hong, 1984, Leukemia research.

Eight-drugs-in-one-day chemotherapy in postirradiated adult patients with malignant gliomas.

J. Finlay, D. Trump, H. Robins, 1989, Medical and pediatric oncology.

Overview: cellular immunotherapy of cancer.

R. Mandell, J. Sosman, B. Chen, 1987, Progress in clinical and biological research.

Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.

R. Bechhofer, J. Sosman, B. Storer, 1990, Journal of biological response modifiers.

Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).

B. Storer, N. Rosenthal, K. Moore, 1987, Progress in clinical and biological research.

Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens.

J. Finlay, M. Trigg, L. Meisner, 1986, Experimental hematology.

Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection.

B. Flynn, M. Trigg, J. Hank, 1985, Experimental hematology.

In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.

J. Finlay, M. Trigg, J. Hank, 1986, Cancer research.

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.

B E Storer, B. Storer, R. Brown, 1989, Cancer research.

Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer

J. Hamm, D. Tormey, I. Shemano, 1990, Breast Cancer Research and Treatment.

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

R. Bechhofer, J. Sosman, B. Storer, 1989, Cancer research.

“Eight‐drugs‐in‐one‐day” chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas

D. Trump, H. Robins, R. Steeves, 1989, Cancer.

Phase I study of toremifene in patients with advanced cancer.

D. Haller, J. Hamm, D. Tormey, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 clinical evaluation of recombinant interleukin-2.

R. Bechhofer, B. Storer, K. Moore, 1987, Progress in clinical and biological research.

Status and potential of interleukin-2 for the treatment of neoplastic disease.

J. Hank, P. Sondel, P. C. Kohler, 1987, Oncology.